Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more
Gemina Laboratories Ltd (GLABF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of January 2025: 0.008x
Based on the latest financial reports, Gemina Laboratories Ltd (GLABF) has a cash flow conversion efficiency ratio of 0.008x as of January 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.81K) by net assets ($-4.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gemina Laboratories Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Gemina Laboratories Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Gemina Laboratories Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gemina Laboratories Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electrocore LLC
NASDAQ:ECOR
|
1.555x |
|
Silver One Resources Inc
OTCQX:SLVRF
|
-0.009x |
|
Sotherly Hotels Inc
NASDAQ:SOHO
|
-0.010x |
|
Sernova Corp
OTCQB:SEOVF
|
0.007x |
|
Medicalg
WAR:MDG
|
-0.001x |
|
Archer Materials Limited
PINK:ARRXF
|
-0.180x |
|
YAS Co., Ltd.
KQ:255440
|
-0.027x |
|
Top High Image
TWO:3284
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Gemina Laboratories Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of Gemina Laboratories Ltd from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | $-4.44 Million | $-1.30 Million | 0.293x | -85.66% |
| 2024-01-31 | $-1.59 Million | $-3.24 Million | 2.046x | -96.74% |
| 2023-01-31 | $-71.81K | $-4.51 Million | 62.798x | +1631.50% |
| 2022-01-31 | $944.23K | $-3.87 Million | -4.100x | -105.55% |
| 2021-01-31 | $159.96K | $-319.09K | -1.995x | -- |